Table 2.

Odds of continuing treatment beyond 30, 90, and 180 days by patient and practice level variables. Full model with overlapping patient and practice variables

Continuation beyond 30 daysContinuation beyond 90 daysContinuation beyond 180 days
OR95% CIP-valueOR95% CIP-valueOR95% CIP-value
Patient variables
  Male1.000.94 to 1.060.950.920.87 to 0.980.010.920.86 to 1.000.04
  Deprivationa0.980.95 to 1.010.180.960.93 to 0.990.0070.970.93 to 1.000.07
  Age 35–64 years1.251.18 to 1.34<0.0011.401.32 to 1.50<0.0011.531.41 to 1.66<0.001
  Age ≥65 years1.131.04 to 1.230.0061.391.27 to 1.52<0.0011.831.64 to 2.05<0.001
  Episode codedb1.991.85 to 2.14<0.0011.701.59 to 1.83<0.0011.561.44 to 1.70<0.001
Practice variables
  Female GPsc1.231.00 to 1.500.041.190.98 to 1.450.091.341.06 to 1.680.01
  Deprivationd0.970.93 to 1.010.110.980.94 to 1.020.311.000.95 to 1.040.90
  Practice list sizee1.000.99 to 1.020.671.000.99 to 1.010.991.001.00 to 1.000.63
  Episodes codedf0.810.63 to 1.030.080.810.64 to 1.020.080.900.69 to 1.180.46
  Prescribing rateg1.000.99 to 1.000.221.000.99 to 1.010.640.990.98 to 1.000.14
  • Model fit described using Akaike Information Criterion. Values for 30 days = 28 043; 90 days = 26 170, and 180 days = 17 618.

  • a Per category of the 7 category DepCat measure.

  • b Entry during the treatment period of a Read Code for a depression or anxiety disorder.

  • c Proportion of GPs in the practice who were female not adjusted for part-time working.

  • d Per DepCat category of the practice main address.

  • e List size in thousands.

  • f Proportion of cases with one or more Read Codes indicative of depression or anxiety during the treatment period.

  • g Patients prescribed new antidepressant treatment per thousand registered patients.